Alteration of kynurenic acid concentration in rat plasma following optically pure kynurenine administration: A comparative study between enantiomers

Chirality

Volumn 21, Issue 4, 2009, Pages 468-472

  Fukushima, Takeshi ^a,b   Sone, Yukiko ^a   Mitsuhashi, Shogo ^a   Tomiya, Masayuki ^a   Toyo'Oka, Toshimasa ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b TOHO UNIVERSITY   (Japan)

Author keywords

Columnswitching high performance liquid chromatography; D kynurenine; Kynurenic acid; L kynurenine; Rat plasma

Indexed keywords

5 METHYL 3 PYRAZOLECARBOXYLIC ACID; ENZYME INHIBITOR; KYNURENIC ACID; PLASMA PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; ANIMAL EXPERIMENT; ARTICLE; BINDING ASSAY; BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; ENANTIOMER; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOMERISM; MALE; METABOLISM; METABOLITE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN BINDING; PURIFICATION; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; D-AMINO-ACID OXIDASE; DEOXYADENOSINES; KYNURENIC ACID; KYNURENINE; MALE; MODELS, CHEMICAL; PROTEIN BINDING; PYRAZOLES; PYRENES; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; TIME FACTORS;

EID: 65549116075     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20620     Document Type: Article

References (35)

1. Nemeth H, Toldi J, Vecsei L. Role of kynurenines in the central and peripherial nervous systems. Curr Neurovascul Res 2005;2:249-260.
2. Ruddick JP, Evans AK, Nutt DJ, Lightman SL, Rook GAW, Lowry CA. Tryptophan metabolism in the central nervous system: medical implications. Exp Rev Mol Med 2006;8:1-27.
3. Swartz KJ, During MJ, Freese A, Beal MF. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J Neurosci 1990;10:2965-2973.
4. Hilmas C, Pereira EFR, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001;21:7463-7473.
5. Hashimoto K, Koike K, Shimizu E, Iyo M. α7 nicotinic receptor agonists as potential therapeutic drugs for schizophrenia. Curr Med Chem 2005;5:171-184.
6. Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol Behav 2007;92: 203-209.
7. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001;313:96-98.
8. Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindstrom LH, Nordin C, Karanti A, Persson P, Erhardt S. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 2005;80:315-322.
9. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001;50:521-530.
10. Mitsuhashi S, Fukushima T, Kawai J, Tomiya M, Santa T, Imai K, Toyo'oka T. Improved method for the determination of kynurenic acid in rat plasma by column-switching HPLC with post-column fluorescence detection. Anal Chim Acta 2006;562:36-43.
11. Becker A, Peters B, Schroeder H, Mann T, Huether G, Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:687-700.
12. Becker A, Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1267-1277.
13. Rossi F, Han Q, Li JS, Li JY, Rizzi M. Crystal structure of human kynurenine aminotransferase I. J Biol Chem 2004;279:50214-50220.
14. Rossi F, Garavaglia S, Montalbano V, Walsh MA, Rizzi M. Crystal structure of human kynurenine aminotransferase II, a drug target for the treatment of schizophrenia. J Biol Chem 2008;283:3559-3566.
15. Borchers R, Berg CP, Whitman NE. Tryptophane metabolism. X. The effect of feeding l(-), dl,- and d(+)- tryptophane, d(-) and dlβ-3-indolelactic acid, β-3-indolepyruvic acid, and l(-)-kynurenine upon the storage of liver glycogen and the urinary output of kynurenic acid, kynurenine, and total acetone bodies. J Biol Chem 1942;145:657-666.
16. Mason M, Berg CP. The metabolism of D- and L-tryptophan and D- and L-kynurenine by liver and kidney preparations. J Biol Chem 1952; 195:515-524.
17. Higuchi K, Hayaishi O. Enzymic formation of D-kynurenine from Dtryptophan. Arch Biochem Biophys 1967;120:397-403.
18. Langner RR, Berg CP. Metabolism of D-tryptophan in the normal human subject. J Biol Chem 1955;214:699-707.
19. Loh HH, Berg CP. Production of D-kynurenine and other metabolites from D-tryptophan by the intact rabbit and by rabbit tissue. J Nutr 1971;101:465-476.
20. Fukushima T, Mitsuhashi S, Tomiya M, Iyo M, Hashimoto K, Toyo'oka T. Determination of kynurenic acid in human serum and its correlation with the concentration of certain amino acids. Clin Chim Acta 2007;377:174-178.
21. Fukushima T, Mitsuhashi S, Tomiya M, Kawai J, Hashimoto K, Toyo'oka T. Determination of rat brain kynurenic acid by column-switching HPLC with fluorescence detection. Biomed Chromatogr 2007;21:514-519.
22. Adage T, Trillat AC, Quattropani A, Perrin D, Cavarec L, Shaw J, Guerassimenko O, Giachetti C, Greco B, Chumakov I, Halazy S, Roach A, Zaratin P. In vitro and in vivo pharmacological profile of AS057278, a selective D-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol 2008;18:200-214.
23. Mitsuhashi S, Fukushima T, Arai K, Tomiya M, Santa T, Imai K, Toyo'oka T. Development of a column-switching high-performance liquid chromatography for kynurenine enantiomers and its application to a pharmacokinetic study in rat plasma. Anal Chim Acta 2007;587:60-66.
24. Speciale C, Schwarcz R. Uptake of kynurenine into rat brain slices. J Neurochem 1990;54:156-163.
25. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991;56:2007-2017.
26. Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 2004;56: 255-260.
27. Okuno E, Schmidt W, Parks DA, Nakamura M, Schwarcz R. Measurement of rat brain kynurenine aminotransferase at physiological kynurenine concentrations. J Neurochem 1991;57:533-540.
28. Guidetti P, Okuno E, Schwarcz R. Characterization of rat brain kynurenine aminotransferases I and II. J Neurosci Res 1997;50:457-465.
29. Corvin A, Donohoe G, McGhee K, Murphy K, Kenny N, Schwaiger S, Nangle JM,Morris D, Gill M. D-Amino acid oxidase (DAO) genotype and mood symptomatology in schizophrenia. Neurosci Lett 2007;426:97-100.
30. Pilone MS. D-Amino acid oxidase: new findings. Cell Mol Life Sci 2000;57:1732-1747.
31. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44:1081-1089.
32. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M. Decreased serum levels of D-serine in patients with schizophrenia. Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003;60:572-576.
33. Batabyal D, Yeh SR. Human tryptophan dioxygenase: a comparison to indoleamine 2,3-dioxygenase. J Am Chem Soc 2007;129:15690-15701.
34. Zhao SL, Liu YM. Electrophoretic separation of tryptophan enantiomers in biological samples. Electrophoresis 2001;22:2769-2774.
35. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 2004;15:618-629.